Cantor Fitzgerald Estimates VERV FY2025 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Verve Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will post earnings per share of ($2.67) for the year. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.11. The company had revenue of $6.87 million during the quarter, compared to analysts’ expectations of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. During the same period last year, the firm posted ($0.72) earnings per share. The business’s revenue was up 120.2% on a year-over-year basis.

A number of other research firms have also recently issued reports on VERV. HC Wainwright cut their target price on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Royal Bank of Canada dropped their price target on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group upped their price objective on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

Verve Therapeutics Price Performance

VERV stock opened at $7.99 on Wednesday. Verve Therapeutics has a one year low of $4.30 and a one year high of $19.34. The stock has a market cap of $676.47 million, a price-to-earnings ratio of -3.25 and a beta of 1.68. The company has a fifty day moving average price of $5.89 and a two-hundred day moving average price of $5.80.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp raised its position in shares of Verve Therapeutics by 27.0% in the third quarter. State Street Corp now owns 4,253,217 shares of the company’s stock valued at $20,586,000 after buying an additional 903,809 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Verve Therapeutics by 72.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company’s stock worth $7,547,000 after acquiring an additional 653,578 shares during the period. Braidwell LP acquired a new position in Verve Therapeutics in the 3rd quarter valued at $3,020,000. Novo Holdings A S lifted its position in shares of Verve Therapeutics by 20.0% during the 2nd quarter. Novo Holdings A S now owns 2,400,000 shares of the company’s stock valued at $11,712,000 after acquiring an additional 400,000 shares during the period. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of Verve Therapeutics by 245.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 395,699 shares of the company’s stock worth $1,931,000 after purchasing an additional 281,173 shares in the last quarter. Institutional investors and hedge funds own 97.11% of the company’s stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.